HK1215170A1 - 治療精神分裂症的方法和組合物 - Google Patents

治療精神分裂症的方法和組合物 Download PDF

Info

Publication number
HK1215170A1
HK1215170A1 HK16103149.6A HK16103149A HK1215170A1 HK 1215170 A1 HK1215170 A1 HK 1215170A1 HK 16103149 A HK16103149 A HK 16103149A HK 1215170 A1 HK1215170 A1 HK 1215170A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating schizophrenia
schizophrenia
treating
Prior art date
Application number
HK16103149.6A
Other languages
English (en)
Chinese (zh)
Inventor
Michela Gallagher
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of HK1215170A1 publication Critical patent/HK1215170A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16103149.6A 2012-11-14 2013-11-14 治療精神分裂症的方法和組合物 HK1215170A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726440P 2012-11-14 2012-11-14
US61/726,440 2012-11-14
PCT/US2013/070144 WO2014078568A1 (en) 2012-11-14 2013-11-14 Methods and compositions for treating schizophrenia

Publications (1)

Publication Number Publication Date
HK1215170A1 true HK1215170A1 (zh) 2016-08-19

Family

ID=50731694

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103149.6A HK1215170A1 (zh) 2012-11-14 2013-11-14 治療精神分裂症的方法和組合物

Country Status (6)

Country Link
US (3) US10154988B2 (enExample)
EP (2) EP3610890B1 (enExample)
JP (2) JP6440625B2 (enExample)
CA (1) CA2891122C (enExample)
HK (1) HK1215170A1 (enExample)
WO (1) WO2014078568A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
PL3096790T3 (pl) * 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
KR101634440B1 (ko) 2014-08-21 2016-06-30 서울대학교산학협력단 AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
CN106109402A (zh) * 2016-07-20 2016-11-16 南通雅本化学有限公司 一种左乙拉西坦注射液
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
US11253173B1 (en) * 2017-05-30 2022-02-22 Verily Life Sciences Llc Digital characterization of movement to detect and monitor disorders
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
JP7867287B2 (ja) * 2020-07-10 2026-05-29 エージンバイオ， インコーポレイテッド Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法

Family Cites Families (731)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516A (en) 1848-04-18 Combining lantebns and lamps
US759A (en) 1838-05-30 Reacting watek-wheels
US1015498A (en) 1911-03-01 1912-01-23 Edward L Kraus Folding-desk blackboard.
IT535124A (enExample) 1952-09-20
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JP2000319257A (ja) 1969-01-06 2000-11-21 Eisai Co Ltd １−ベンジル−４−［（５，６−ジメトキシ−２−フルオロ−１−インダノン）−２−イル］メチルピペリジン
US3953603A (en) 1973-11-05 1976-04-27 Eli Lilly And Company Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
IT1045043B (it) 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
IT1075280B (it) 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
ATE27T1 (de) 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4337250A (en) 1979-07-30 1982-06-29 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4352807A (en) 1979-07-30 1982-10-05 Pfizer Inc. Hexahydro-trans-pyridoindole neuroleptic agents
US4431649A (en) 1979-07-30 1984-02-14 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4465683A (en) 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4372960A (en) 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
US4427679A (en) 1981-01-16 1984-01-24 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
FR2515179A1 (fr) 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
US4415085A (en) 1981-12-21 1983-11-15 Eli Lilly And Company Dry pharmaceutical system
PT77267B (en) 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
PT77268B (en) 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel bridged hexahydrobenz <f> isoquinolines or compounds relating thereto
US4879391A (en) 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4977178A (en) 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4495187A (en) 1982-10-18 1985-01-22 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4547501A (en) 1983-09-02 1985-10-15 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
US4599339A (en) 1983-09-26 1986-07-08 Eli Lilly And Company Use of pyrimido[4,5-g]quinolines in treating parkinsonism
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4593037A (en) 1984-07-26 1986-06-03 Pfizer Inc. 1,3-disubstituted piperidine compounds as neuroleptic agents
US4619930A (en) 1985-01-16 1986-10-28 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4656173A (en) 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
US4677104A (en) 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
JPS6222785A (ja) 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4757073A (en) 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
DD263531A5 (de) 1986-10-21 1989-01-04 ������@���Kk�� Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
MX174210B (es) 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
PH25124A (en) 1987-03-17 1991-02-19 Hoechst Roussel Pharma Substituted 9-amino-tetrahydro acridines and related compounds
DE3709230A1 (de) 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US4784998A (en) 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
US4931447A (en) 1987-06-15 1990-06-05 Eli Lilly And Company Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPS6422883A (en) 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
ZA886585B (en) 1987-09-08 1990-05-30 Lilly Co Eli Specific 5-ht,antagonists
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5001130A (en) 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5238959A (en) 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5242911A (en) 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
US5077295A (en) 1988-09-16 1991-12-31 Pfizer Inc. Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
HU207310B (en) 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
US4950658A (en) 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
HUT53607A (en) 1989-01-17 1990-11-28 Hoffmann La Roche Process for production of derivatives of cyclohexan-acetamid
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US4914207A (en) 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
US4963689A (en) 1989-05-19 1990-10-16 Pfizer Inc. Heterocyclicguanidines as 5HT3 antagonists
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
IT1231477B (it) 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5006525A (en) 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5011841B1 (en) 1989-11-14 1994-09-06 Pfizer Treatment of depression
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
US5043341A (en) 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JPH072740B2 (ja) 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
DE69106365T2 (de) 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (enExample) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
ATE121389T1 (de) 1990-09-28 1995-05-15 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
HU225055B1 (en) 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5147881A (en) 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
TW197435B (enExample) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
JPH04327532A (ja) 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
DE69200921T2 (de) 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
PL171914B1 (pl) 1991-03-28 1997-06-30 Eisai Co Ltd Sposób wytwarzania pochodnych aminy heterocyklicznej PL PL PL PL PL PL PL
US5817655A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817656A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5104880A (en) 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5716965A (en) 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
BR9206073A (pt) 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
SK282203B6 (sk) 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
EP0597956A1 (en) 1991-07-29 1994-05-25 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5161533A (en) 1991-09-19 1992-11-10 Xomed-Treace Inc. Break-apart needle electrode system for monitoring facial EMG
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
ES2096099T3 (es) 1991-09-25 1997-03-01 Pfizer Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
EP0607164B1 (en) 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
CA2080536A1 (en) 1991-10-17 1993-04-18 John S. Ward Nicotinic activity of a series of arecolones and isoarecolones
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
ES2111650T3 (es) 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
CA2124206C (en) 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
US5137894A (en) 1991-12-05 1992-08-11 New James S 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
CA2129732A1 (en) 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
TW288010B (enExample) 1992-03-05 1996-10-11 Pfizer
US5569662A (en) 1992-03-23 1996-10-29 Pfizer Inc. Quinuclidine derivatives as substance P antagonists
AU670579B2 (en) 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
EP0635015B1 (en) 1992-04-10 1997-01-29 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5256664A (en) 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
US20050256162A1 (en) 1992-05-05 2005-11-17 Pfizer Inc Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
DE69331190T2 (de) 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
AU4396193A (en) 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
JP2909214B2 (ja) 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
US5604241A (en) 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
US5837711A (en) 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
TW251284B (enExample) 1992-11-02 1995-07-11 Pfizer
US5498610A (en) 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
NZ254604A (en) 1992-11-12 1997-06-24 Pfizer Quinuclidine derivative and pharmaceutical compositions thereof
US6369074B1 (en) 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
ES2147759T3 (es) 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
BR9307646A (pt) 1992-12-17 1999-05-25 Pfizer Pirrolopirimidinas como antagonistas de crf
EP0611769A1 (en) 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
WO1994020476A1 (fr) 1993-03-02 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Nouveau compose heterocyclique
EP0687268B1 (en) 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
WO1994021619A1 (en) 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
CA2167198C (en) 1993-07-15 1999-03-16 Kunio Satake Benzylaminoquinuclidines
AU686654B2 (en) 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
US6083943A (en) 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
US5703065A (en) 1993-09-17 1997-12-30 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
ATE167057T1 (de) 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
ES2223049T3 (es) 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
ES2135062T3 (es) 1994-06-16 1999-10-16 Pfizer Pirazolo y pirrolopiridinas.
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
MX9700080A (es) 1994-06-29 1997-04-30 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
RU2139857C1 (ru) 1994-08-18 1999-10-20 Пфайзер Инк. Производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4-гидроксифенил)-2-(пиперидинил-1)-алканола, фармацевтическая композиция и способ связывания nmda рецептора
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5627200A (en) 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1996032944A1 (en) 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
US5889010A (en) 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US20010023248A1 (en) 1995-05-25 2001-09-20 Howard Harry R. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP3042894B2 (ja) 1995-07-07 2000-05-22 ファイザー製薬株式会社 サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
US5696168A (en) 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IL122984A0 (en) 1995-07-24 1998-08-16 Lilly Co Eli Treatment of attention-deficit/ hyperactivity disorder
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
ATE240942T1 (de) 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
US5783584A (en) 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
PT780375E (pt) 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
EP0868185A4 (en) 1995-12-22 2002-04-10 Lilly Co Eli METHOD FOR TREATING DEPRESSIONS
US5625897A (en) 1996-01-11 1997-05-06 Park; Kelly R. Upper torso garment
ATE290859T1 (de) 1996-01-22 2005-04-15 Lilly Co Eli Indanderivate für antipsychotische mittel
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
WO1997033577A1 (en) 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
NZ326874A (en) 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
HUP9902160A3 (en) 1996-03-29 2001-02-28 Pfizer Benzyl(idene)-lactam derivatives, their use as selective (ant)agonists of 5-ht1a-and/or 5-ht1d receptors, pharmaceutical compositions containing these compounds
WO1997038993A1 (en) 1996-04-12 1997-10-23 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TR199802241T2 (enExample) 1996-05-07 1999-02-22 Pfizer Inc.
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP1380298A3 (en) 1996-05-23 2004-04-07 Bristol-Myers Squibb Pharma Company Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
DK0810220T3 (da) 1996-05-28 2002-03-18 Pfizer Arylacrylamidderivater som 5-HT1-agonister eller -antagonister
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
EP0821955B1 (en) 1996-08-01 2002-02-20 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
US6117890A (en) 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6043258A (en) 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
MX9706196A (es) 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
WO1998007431A1 (en) 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
AU720366B2 (en) 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
AU4394897A (en) 1996-10-30 1998-05-22 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and the ir use in addiction therapy
WO1998030243A1 (en) 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
DE69815090T2 (de) 1997-03-03 2004-02-19 Eisai Co., Ltd. Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
GB2323788B (en) 1997-04-02 1999-02-17 Bristol Myers Squibb Co Venting valve for ostomy bag
CA2285548C (en) 1997-04-04 2006-07-11 Pfizer Products Inc. Nicotinamide derivatives
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6896098A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia
JP2001520653A (ja) 1997-04-11 2001-10-30 エリ リリー アンド カンパニー 精神分裂病の治療法
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
ES2245015T3 (es) 1997-06-09 2005-12-16 Pfizer Products Inc. Quinazolin-4-onas como antagonistas de ampa.
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
WO1999004778A1 (en) 1997-07-22 1999-02-04 Eli Lilly And Company Pharmaceutical compounds
GB9716879D0 (en) 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
WO1999008672A1 (en) 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
IL125951A (en) 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999029668A1 (en) 1997-12-05 1999-06-17 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
CN1279667A (zh) 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
IL137019A0 (en) 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
AU2495399A (en) 1998-02-06 1999-08-23 Eli Lilly And Company Desert hedgehog related nucleic acids and proteins
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PT957099E (pt) 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
ES2226284T3 (es) 1998-04-16 2005-03-16 Pfizer Products Inc. N-acil y n-aroil-aralquilamidas.
CA2332253A1 (en) 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
HK1040055B (zh) 1998-05-22 2005-04-01 伊莱利利公司 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
GT199900060A (es) 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911068A (pt) 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6436914B1 (en) 1998-06-30 2002-08-20 Bristol-Myers Squibb Company 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EA200100124A1 (ru) 1998-08-11 2001-10-22 Пфайзер Продактс Инк. Замещенные 1,8-нафтиридин-4(1h)-оны в качестве ингибиторов фосфодиэстеразы 4
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
AU6472799A (en) 1998-10-16 2000-05-08 Janssen Pharmaceutica N.V. Therapy for improving cognition
US5994352A (en) 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
CA2354035A1 (en) 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU2180400A (en) 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
DE60018225T2 (de) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
US6277866B1 (en) 1999-03-03 2001-08-21 Eisai Co., Ltd. 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
US6372760B1 (en) 1999-03-31 2002-04-16 Eisai Co., Ltd. Stabilized composition comprising antidementia medicament
EP1050303A3 (en) 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
PL358538A1 (en) 1999-05-21 2004-08-09 Pfizer Products Inc. New pharmaceutical combinations for nos inhibitors
AU4973800A (en) 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6524616B1 (en) 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
JP4242048B2 (ja) 1999-09-01 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−置換ピペリジン誘導体
ES2284519T3 (es) 1999-09-01 2007-11-16 EISAI R&amp;D MANAGEMENT CO., LTD. Derivados de piperidina 4-sustituida.
HK1043590A1 (zh) 1999-09-22 2002-09-20 Schering Corporation 毒蕈碱性拮抗物
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
CA2324813A1 (en) 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
CA2392879C (en) * 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
EP1244666A1 (en) 1999-12-17 2002-10-02 Bristol-Myers Squibb Pharma Company Imidazopyrimidinyl and imidazopyridinyl derivatives
EP1242072A4 (en) 1999-12-17 2004-02-04 Bristol Myers Squibb Co ANTIPSYCHOTIC HETEROCYCLIC COMPOUNDS
EP1246822A1 (en) 1999-12-20 2002-10-09 Eli Lilly And Company Benzofuran derivatives
EP1242411B1 (en) 1999-12-20 2006-03-08 Eli Lilly And Company Indole derivatives for the treatment of depression and anxiety
WO2001046186A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Benzofuran derivatives
EP1242419A1 (en) 1999-12-20 2002-09-25 Eli Lilly And Company Azabicyclo 3.2.1]octane derivatives
WO2001046179A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
PT1113015E (pt) 1999-12-29 2004-12-31 Pfizer Prod Inc Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
PL201790B1 (pl) 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
AU2001239052A1 (en) 2000-03-06 2001-09-17 Immune Network Ltd. Compositions for prevention and treatment of dementia
AU2001241512A1 (en) 2000-03-13 2001-09-24 Eli Lilly And Company Sulfonamide derivatives
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
KR20020089420A (ko) 2000-03-31 2002-11-29 화이자 프로덕츠 인코포레이티드 갑상선 수용체 리간드로서의 말로남산 및 그의 유도체
DE50111799D1 (de) 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
HUP0300413A2 (hu) 2000-04-10 2003-06-28 Pfizer Products Inc. Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1285656A4 (en) 2000-04-13 2006-07-12 Eisai Co Ltd ACETYLCHOLINESTERASE HEMMER CONTAINING 1-BENZYLPYRIDINIUM SALT
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20040229911A1 (en) 2000-05-17 2004-11-18 Pfizer Inc New pharmaceutical combinations for NOS inhibitors
AU2001261022A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
US6893858B2 (en) 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
KR20030007824A (ko) 2000-06-02 2003-01-23 화이자 프로덕츠 인크. 정신의학적 장애 및 안질환의 치료를 위한ｓ-메틸-디히드로-지프라시돈
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
WO2002003684A2 (en) 2000-06-30 2002-01-10 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
AU2001282913A1 (en) 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
WO2002024200A1 (en) 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
US20020103198A1 (en) 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
MXPA03005355A (es) 2000-12-20 2004-05-27 Bristol Myers Squibb Co Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina.
HUP0303513A3 (en) 2000-12-20 2005-12-28 Bristol Myers Squibb Pharma Co Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
KR100823668B1 (ko) 2000-12-28 2008-04-21 해밀턴 파마슈티컬스 인코포레이티드 신경성 통증 치료 및 예방약
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6888004B2 (en) 2001-01-26 2005-05-03 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
WO2002067931A1 (en) 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
ES2282401T3 (es) 2001-03-13 2007-10-16 Bristol-Myers Squibb Pharma Company 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina.
JP2004532200A (ja) 2001-03-15 2004-10-21 サエジス ファーマシューティカルズ， インコーポレイテッド 全身性ストレスの後に認識機能を回復するための方法
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
CZ20032644A3 (en) 2001-03-29 2004-06-16 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
EP1666886A3 (en) 2001-04-20 2006-06-21 Pfizer Products Inc. Method of identifying selective PDE10 inhibitor compounds
US20030018047A1 (en) 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2756602A (en) 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
DE60208630T2 (de) 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
WO2002092090A1 (en) 2001-05-14 2002-11-21 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
EP1260221A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
AU2002354575A1 (en) 2001-07-12 2003-01-29 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2003009851A1 (en) 2001-07-24 2003-02-06 Bristol-Myers Squibb Company R-6-hydroxy-buspirone
WO2003010161A1 (en) 2001-07-24 2003-02-06 Bristol-Myers Squibb Company S-6-hydroxy-buspirone
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
ATE305917T1 (de) 2001-08-16 2005-10-15 Pfizer Prod Inc Difluormethylen aromatische ether und ihre verwendung als inhibitoren des glycin-typ-1- transporters
ATE404192T1 (de) 2001-08-22 2008-08-15 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
CA2459146A1 (en) 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
US20040235957A1 (en) 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
WO2003032981A1 (en) 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
KR20010113584A (ko) 2001-11-08 2001-12-28 (주)시스튜디오 컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체
US6673811B1 (en) 2001-11-19 2004-01-06 Neurogen Corporation 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA02010430A (es) 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
JP2005517647A (ja) 2001-12-11 2005-06-16 イーライ・リリー・アンド・カンパニー ノルエピネフリン再取り込み阻害物質の認知不全処置への使用
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US20050009927A1 (en) 2002-01-23 2005-01-13 Pfizer Inc Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
WO2003072107A1 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
US20040167200A1 (en) 2002-03-25 2004-08-26 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
EP1492794B1 (en) 2002-03-28 2007-12-12 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
US6759552B2 (en) 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
ES2297141T3 (es) 2002-03-29 2008-05-01 EISAI R&amp;D MANAGEMENT CO., LTD. Derivados de (1-indanona)-(1,2,3,6-tetrahidropiridina).
WO2003084610A1 (en) 2002-04-03 2003-10-16 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
DE60324544D1 (de) 2002-04-26 2008-12-18 Schering Corp Muskarin antagonisten
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1509232B1 (en) 2002-05-31 2008-11-19 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040001895A1 (en) 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
US20040116506A1 (en) 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
GB0219153D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Substituted glycine derivatives for use as medicaments
GB0219154D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
NZ537995A (en) 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
CA2498291C (en) 2002-09-10 2009-04-07 Pfizer Products Inc. Diazabicyclic compounds useful in the treatment of cns and other disorders
TW200418838A (en) 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
WO2004026236A2 (en) 2002-09-18 2004-04-01 Bristol-Myers Squibb Company Cyclopentyl indole derivatives
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
GB0223494D0 (en) 2002-10-09 2002-11-13 Neuropharma Sa Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
PL376721A1 (pl) 2002-10-24 2006-01-09 Pfizer Products Inc. Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
GB0225379D0 (en) 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
JP2006508975A (ja) 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド
EP1565190A4 (en) 2002-11-22 2006-04-26 Bristol Myers Squibb Co ARYLCYCLOPROPYLCARBOXYLIC ACID AMIDE AS A KALIUM CHANNEL OPENER
US7135472B2 (en) 2002-11-22 2006-11-14 Bristol-Myers Squibb Company 3-Heterocyclic benzylamide derivatives as potassium channel openers
MXPA05005398A (es) 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
AU2003294443A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
EP1581498A2 (en) 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
WO2004051222A2 (en) 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7090985B2 (en) 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
AU2003279492A1 (en) 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
CA2509142A1 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
CA2514656A1 (en) 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists
ZA200507322B (en) 2003-03-06 2007-03-28 Celgene Corp Selective cytokine inhibitory drugs for treating disorders of the central nervous system
BRPI0408248A (pt) 2003-03-12 2006-03-01 Pfizer Prod Inc derivados azabicìclicos de piridiloximetila e de benzisoxazol
US20040191334A1 (en) 2003-03-24 2004-09-30 Pang-Chui Shaw Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
EP1613629A1 (en) 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
BRPI0409307A (pt) 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
MXPA05011387A (es) 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
GB0309440D0 (en) 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2006525309A (ja) 2003-05-07 2006-11-09 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ピロロ（１，２−ｂ）ピリダジン化合物、ならびにＣＲＦ−１受容体拮抗薬としてのその使用
EP1625115A1 (en) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Substituted pyrimidine derivatives
JP2007502856A (ja) 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
EP1626722A1 (en) 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
KR20060009938A (ko) 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
ZA200508306B (en) 2003-05-23 2007-03-28 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US7101881B2 (en) 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
MXPA05013756A (es) 2003-06-18 2006-03-08 Pfizer Prod Inc Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.
CA2525245C (en) 2003-06-27 2010-10-19 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
DK1641454T3 (da) 2003-06-27 2009-02-09 Pfizer Prod Inc Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
US20050070577A1 (en) 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005013961A1 (en) 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
MXPA06002778A (es) 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
CA2536107A1 (en) 2003-09-09 2005-03-24 Eli Lilly And Company Substituted piperazines of azepines, oxazepines, and thiazepines
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
WO2005040110A1 (en) 2003-10-08 2005-05-06 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
WO2005039580A1 (en) 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
AU2004281229A1 (en) 2003-10-16 2005-04-28 Pfizer Products Inc. Preparation of 3-azabicyclo (3.1.0) hexane derivatives
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
WO2005053701A1 (en) 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
CA2547283C (en) 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
CA2546970C (en) 2003-12-02 2011-04-26 Ucb, S.A. Imidazole derivatives, processes for preparing them and their uses
KR20060121178A (ko) 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
MXPA06006812A (es) 2003-12-15 2006-08-23 Pfizer Prod Inc Lactamas e imidas aralquilo y aralqulideno heterociclicas.
US20050227980A1 (en) 2003-12-15 2005-10-13 Pfizer Inc. Aralkyl and aralkylidene heterocyclic lactam and imides
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US20050171095A1 (en) 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
WO2005070916A1 (en) 2004-01-09 2005-08-04 Eli Lilly And Company Thiophene and furan compounds
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
BRPI0507190A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
BRPI0507250A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
CA2556160A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
CA2556390C (en) 2004-02-25 2012-10-02 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
US20060166998A1 (en) 2004-03-12 2006-07-27 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US20060148807A1 (en) 2004-03-12 2006-07-06 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
ES2374629T3 (es) 2004-03-17 2012-02-20 Pfizer Products Incorporated Nuevos derivados de bencil(iden)-lactama.
JP2007529556A (ja) 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2005102272A2 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Sustained-release dosage forms for cabergoline
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
US20050245543A1 (en) 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
WO2005107808A2 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2567483A1 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
BRPI0511195A (pt) 2004-05-21 2007-12-04 Pfizer Prod Inc tetraidronaftilpiperazinas como antagonistas da 5-ht1b, agonistas inversos e agonistas parciais
EP1758600A4 (en) * 2004-06-04 2008-03-05 Mood Man Sciences Llc METHOD AND COMPOSITIONS FOR TREATING MUTUAL DISORDER
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
CN1964942A (zh) 2004-06-11 2007-05-16 Ucb股份有限公司 通过分子内烯丙基化制备2－氧代－1－吡咯烷衍生物的方法
BRPI0512567A (pt) 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
EP1768975A2 (en) 2004-06-25 2007-04-04 Pfizer Products Inc. Pyridyl piperazines for the treatment of cns disorders
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
EP1771449A1 (en) 2004-07-21 2007-04-11 Pfizer Products Incorporated Histamine-3 receptor antagonists
JP2008509212A (ja) 2004-08-09 2008-03-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤
WO2006024955A1 (en) 2004-09-01 2006-03-09 Pfizer Products Inc. Azabicyclic amine histamine-3 receptor antagonists
JP2008512440A (ja) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法
BRPI0514675A (pt) 2004-09-10 2008-06-17 Pfizer Prod Inc ligantes de éter difenìlico terapêuticos
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
EP1807087A2 (en) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
MX2007004485A (es) 2004-10-15 2007-06-13 Organon Nv Tratamiento de desordenes bipolares y sintomas asociados.
ATE504582T1 (de) 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
ES2336130T3 (es) 2004-10-18 2010-04-08 Eli Lilly And Company Derivados 1-(hetero)aril-3-amino-pirrolidina para uso como antagonistas del receptor de mglur3.
WO2006060082A1 (en) 2004-10-22 2006-06-08 THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006051394A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
JP2008519820A (ja) 2004-11-15 2008-06-12 ファイザー・プロダクツ・インク Ｃｎｓ障害の治療のためのアザベンゾオキサゾール
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
EA012245B1 (ru) 2004-11-29 2009-08-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эд-Эл-Си Терапевтические пиразоло[3,4-b]пиридины и индазолы
ATE395348T1 (de) 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
EP2425846A1 (en) 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
EP1831172B1 (en) 2004-12-28 2009-02-18 Council of Scientific and Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
AU2005325930B2 (en) 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
FR2881618B1 (fr) 2005-02-10 2007-04-13 Centre Nat Rech Scient Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US20070298098A1 (en) 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
ES2403069T3 (es) 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
WO2006090272A1 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006102750A1 (en) 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
EA200701856A1 (ru) 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
WO2006106416A1 (en) 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
MX2007012463A (es) 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7456188B1 (en) 2005-04-28 2008-11-25 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
EP1890700A2 (en) * 2005-05-31 2008-02-27 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EP1731149A1 (en) 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US20070015763A1 (en) 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
MX2008000811A (es) 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007017750A1 (en) 2005-08-08 2007-02-15 Pfizer Products Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
WO2007026219A2 (en) 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
US8420631B2 (en) 2005-09-01 2013-04-16 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
WO2007028132A2 (en) 2005-09-01 2007-03-08 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
EP1924561B1 (en) 2005-09-01 2012-11-14 Eli Lilly & Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
PT1924560E (pt) 2005-09-01 2009-10-23 Lilly Co Eli 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c
US20090215857A1 (en) 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
EP1963325A2 (en) 2005-12-07 2008-09-03 UCB Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007096743A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
WO2007107846A1 (en) 2006-03-20 2007-09-27 Council Of Scientific And Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
US20070224636A1 (en) 2006-03-24 2007-09-27 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
JP2009535394A (ja) 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2041084B1 (en) 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080014271A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
WO2008015516A1 (en) 2006-07-28 2008-02-07 Pfizer Products Inc. Fused tricyclic heterocycles for the treatment of schizophrenia
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008020306A2 (en) 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
EP2051696A2 (en) 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
JP2010503654A (ja) 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
AU2007299726A1 (en) 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TW200825067A (en) 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
RU2478619C2 (ru) 2006-12-11 2013-04-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения ингибиторов холинэстеразы на основе инданона
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
WO2008084324A1 (en) 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
KR101108109B1 (ko) 2007-01-22 2012-02-06 화이자 프로덕츠 인코포레이티드 치료 화합물의 토실레이트 염 및 이의 약학 조성물
US8101782B2 (en) 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
FR2912056B1 (fr) 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
EA017937B1 (ru) 2007-02-07 2013-04-30 Пфайзер Инк. ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
EP2152262A2 (en) 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
WO2008144305A1 (en) 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
RU2339620C1 (ru) 2007-07-09 2008-11-27 Общество С Ограниченной Ответственностью "Фармвинг" Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
US20100168174A1 (en) 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
US20090030403A1 (en) 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
WO2009038412A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
CA2708043C (en) 2007-12-07 2012-11-13 Pfizer Inc. Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
EP2254577A1 (en) * 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
DK2273975T3 (da) 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
WO2009127944A1 (en) 2008-04-17 2009-10-22 Pfizer Inc. Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
BRPI0910775A2 (pt) 2008-04-22 2015-09-29 Lilly Co Eli compostos 1,5-difenil pirrolidin-2-ona como ligantes cb-1
US8426448B2 (en) 2008-04-22 2013-04-23 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010002869A1 (en) 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. 2-oxo-1-pyrrolidine derivatives
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
EP2346500B1 (en) 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
US20100113465A1 (en) 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
WO2010057088A2 (en) 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyrrolidinyl modulators of nicotinic acetylcholine receptors
KR101689688B1 (ko) 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
WO2010058318A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
US20100172979A1 (en) 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
AU2010209790B2 (en) 2009-01-29 2014-01-16 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2406233B1 (en) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
US8846411B2 (en) 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
JP5643818B2 (ja) 2009-06-18 2014-12-17 ファイザー・インク Ｋａｔｉｉ阻害剤としての二環式および三環式化合物
WO2011015349A2 (en) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Methods for enhancing the cognitive function
CN101647789B (zh) 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
EP2486918A4 (en) 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011143721A1 (en) 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CA2809217A1 (en) 2010-09-21 2012-03-29 Pfizer Inc. Pyrimidones for treatment of potassium channel related diseases
RU2541159C2 (ru) 2010-10-26 2015-02-10 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
KR20120055313A (ko) 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
DK2646443T3 (en) 2010-12-01 2014-11-17 Pfizer CAT-II inhibitors
WO2012073146A1 (en) 2010-12-01 2012-06-07 Pfizer Inc. Kat ii inhibitors
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
JP5543039B2 (ja) 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
DE102011103270A1 (de) 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144546A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения

Also Published As

Publication number Publication date
EP3610890B1 (en) 2026-08-12
JP6440625B2 (ja) 2018-12-19
CA2891122C (en) 2021-07-20
CA2891122A1 (en) 2014-05-22
WO2014078568A1 (en) 2014-05-22
EP3610890A1 (en) 2020-02-19
US10624875B2 (en) 2020-04-21
US20180125818A1 (en) 2018-05-10
US10154988B2 (en) 2018-12-18
EP2919788A1 (en) 2015-09-23
JP2015537003A (ja) 2015-12-24
US20140206667A1 (en) 2014-07-24
US20150313876A1 (en) 2015-11-05
JP2018090609A (ja) 2018-06-14
EP2919788A4 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
MX361183B (es) Derivados de 1,4-ciclohexilamina y procesos para la preparación de los mismos.
CL2015002516A1 (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
IN2015DN01156A (enExample)
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
EP2578626A4 (en) RUBBER COMPOSITION FOR TIRE INSULATIONS AND TIRES THEREWITH
BR112013022917A2 (pt) derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace)
EP2799467A4 (en) MANUFACTURING METHOD FOR A RUBBER COMPOSITION, RUBBER COMPOSITION AND AIR TIRES THEREWITH
EP2900548A4 (en) TRIMARAN WITH EXTRACTORS WITH PROPELLERS
PL2714036T3 (pl) Podstawione alifany, cyklofany, heterafany, heterofany, hetero-heterafany i metaloceny użyteczny do leczenia zakażeń hcv
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CO6801738A2 (es) Composición oftálmica de alta concentración de olopatadina
PH12015501609A1 (en) Phenicol antibacterials
WO2012085557A3 (en) Methods and biomarkers for differentially diagnosing psychotic disorders
IN2015KN00073A (enExample)
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
FR2983097B1 (fr) Machine-outil pour l&#39;usinage de pieces en forme d&#39;arbres
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
EP3750564C0 (en) Method of treating articles with carbon dioxide
SG10201900541QA (en) Derivatives of xanthone compounds